Enlivex Therapeutics (ENLV) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ENLV Enlivex Therapeutics

Watchlist

1.300
+0.220+20.37%

Close Dec 3 16:00 ET

1.310
+0.010+0.77%

Pre 06:20 ET

28.59MMarket Cap-1326P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target
BenzingaDec 3 09:36 ET
Express News | Elivex Therapeutics Shares Are Trading Higher After the Company Announced Interim Efficacy Data Showing Statistical Significance and Marked Improvements for Its Allocetra Trial
BenzingaDec 3 09:14 ET
Enlivex Announces Interim Efficacy Data From Allocetra Trial In Patients With Moderate To Severe Knee Osteoarthritis
BenzingaDec 3 08:32 ET
Express News | Enlivex Therapeutics Ltd - Interim Results Show Statistically Significant Improvements in Pain and Functionality
ReutersDec 3 08:30 ET
Enlivex Therapeutics Faces Financial Challenges Amid Losses
TipRanksNov 29 16:58 ET
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3
AccesswireNov 26 10:15 ET

Comments

Jaguar8

13 hours ago

🟢Watchlist Wednesday, December 4. NFA. Check on my previous watchlist. Those without ✅ means they can have delayed market reaction.

Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...

Jaguar8

22 hours ago

NEWS

$Enlivex Therapeutics (ENLV.US)$
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Tuesday, 3rd December at 8:30 am
Nes-Ziona, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive interim efficacy data from the Phase I stage of its randomized, multi-country Phase I/II Allocetra™ tri...

Jaguar8

Nov 20 07:05

NEWS

$Enlivex Therapeutics (ENLV.US)$
Enlivex Adopts Bitcoin Treasury Reserve Strategy

Trytosaveabit

Nov 20 07:03

News

$Enlivex Therapeutics (ENLV.US)$ Benzinga· 1 min ago
Enlivex Board Approves Purchase Of Up To $1M Of Bitcoin

Jaguar8

Nov 14 07:03

NEWS

$Enlivex Therapeutics (ENLV.US)$
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
Enlivex Therapeutics has initiated a Phase I clinical trial evaluating Allocetra™ in patients with psoriatic arthritis. The first patient has completed dosing and initial follow-up with no safety concerns reported. The trial aims to recruit six patients who haven't responded adequately to conventional therapies. The study wi...

Heat List

Overall

No Data